Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the sale, the insider owned 281,763 shares in the company, valued at approximately $7,063,798.41. The trade was a 1.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Denali Therapeutics Price Performance

Shares of Denali Therapeutics stock traded down $0.45 during trading on Thursday, reaching $24.82. 1,346,799 shares of the stock traded hands, compared to its average volume of 1,772,163. The company has a market capitalization of $3.97 billion, a price-to-earnings ratio of -8.74 and a beta of 1.01. The business has a fifty day simple moving average of $23.85 and a two-hundred day simple moving average of $21.43. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. Denali Therapeutics Inc. has a 52-week low of $12.58 and a 52-week high of $27.30.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same quarter in the prior year, the company earned ($0.72) EPS. Sell-side analysts expect that Denali Therapeutics Inc. will post -2.61 EPS for the current year.

Institutional Investors Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Denali Therapeutics during the 2nd quarter valued at about $360,759,000. Vanguard Group Inc. lifted its stake in Denali Therapeutics by 8.9% in the fourth quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock worth $215,586,000 after purchasing an additional 1,064,972 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Denali Therapeutics by 28.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock worth $119,766,000 after purchasing an additional 1,615,565 shares during the last quarter. Temasek Holdings Private Ltd boosted its position in shares of Denali Therapeutics by 30.9% during the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after buying an additional 1,657,142 shares during the period. Finally, State Street Corp grew its stake in shares of Denali Therapeutics by 14.6% during the fourth quarter. State Street Corp now owns 6,263,371 shares of the company’s stock valued at $103,408,000 after buying an additional 799,110 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DNLI shares. Stifel Nicolaus set a $41.00 target price on shares of Denali Therapeutics in a report on Monday, June 22nd. Morgan Stanley lifted their price objective on shares of Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft upped their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Robert W. Baird set a $34.00 price target on Denali Therapeutics in a research report on Friday, August 7th. Finally, BTIG Research reissued a “buy” rating and set a $39.00 price objective on shares of Denali Therapeutics in a research note on Monday, May 11th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $35.92.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.